Longboard pharmaceuticals completes enrollment of phase 1b/2a pacific study evaluating lp352 for the treatment of developmental and epileptic encephalopathies

La jolla, calif.--(business wire)--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has completed enrollment of its phase 1b/2a clinical trial, the pacific study, which is evaluating lp352, an oral, centrally acting 5-ht2c receptor superagonist, in 52 participants with developmental and epileptic encephalopathies (dees). the primary objectives of the.
LBPH Ratings Summary
LBPH Quant Ranking